Innovative Pharmaceutical Biotech Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	8.8yrs
Board average tenure	12.9yrs

Recent management updates

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

CEO

Innovative Pharmaceutical Biotech has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rong Tang	Executive Director	10.1yrs	HK$548.00k	0.023% HK$ 84.0k
Yuan Xing Gao	Executive Director	8.8yrs	HK$1.36m	no data
Tak Yiu Cheng	Executive director	1.3yrs	HK$90.00k	no data
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	4.1yrs	no data	30.52% HK$ 111.5m
Hon Yin Poon	Financial Controller & Company Secretary	11.4yrs	no data	no data
Qi Dong	Sales Head of the Group	no data	no data	no data
Wei Yu	Joint Chairman to the Department of Innovation & Strategic Development and Advisor	no data	no data	no data
Jie Gu	Adviser and Joint Chairman to the Department of Innovation & Strategic Development	8.8yrs	no data	no data
Yi Xie	Chief Executive of United Gane Holdings Limited	no data	no data	no data
Dong Hui	General Manager of the Group and Director of CJV	no data	no data	no data

8.8yrs

Average Tenure

60yo

Average Age

Experienced Management: 399's management team is seasoned and experienced (8.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rong Tang	Executive Director	10.1yrs	HK$548.00k	0.023% HK$ 84.0k
Yuan Xing Gao	Executive Director	8.8yrs	HK$1.36m	no data
Tak Yiu Cheng	Executive director	1.3yrs	HK$90.00k	no data
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	14.1yrs	no data	30.52% HK$ 111.5m
Dong Hui	General Manager of the Group and Director of CJV	no data	no data	no data
Chung Lau	Director of CJV	no data	no data	no data
Weijun Chen	Independent Non-Executive Director	14.9yrs	HK$80.00k	no data
Nian Jiang	Non Executive Chairman	13.8yrs	HK$60.00k	no data
Yanmin Wu	Non-Executive Director	13.3yrs	HK$60.00k	no data
Rongliang Wang	Independent Non-Executive Director	13.3yrs	HK$60.00k	no data
Yan Xiao	Non-Executive Director	12.4yrs	HK$60.00k	no data
Jinzhong Chen	Independent Non-Executive Director	3.7yrs	HK$60.00k	no data

12.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 399's board of directors are seasoned and experienced ( 12.9 years average tenure).

Innovative Pharmaceutical Biotech Management

Management criteria checks 2/4

Key information

Recent management updates

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Less than half of directors are independent

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Less than half of directors are independent

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

New minor risk - Share price stability

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age